Enrolling
Filter By:
Ongoing
CTNPT 043: Endocannabinoid system and inflamm-aging in HIV-associated atherosclerosis
Interplay between expanded endocannabinoid (eCB) system and inflamm-aging: Implication for accelerated atherosclerosis in people living with HIV (PLWH) under ART
Learn MoreEnrolling
CTN 335: The British Columbia CARMA–CHIWOS Collaboration (BCC3)
The role of female sex hormones and chronic/latent co-infections on cellular aging and comorbidities in women living with HIV
Learn MoreReporting
CTN 328-1: Vaccine Confidence in HIV
Understanding COVID-19 vaccine confidence in people living with HIV in Canada: A pan-Canadian survey
Learn MoreEnrolling
CTNPT 047: Letermovir in ART-treated HIV-infected persons
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
Learn MoreReporting
CTNPT 045: Immune Response to COVID-19 Vaccination in People with HIV
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreEnrolling
CTN 326: LIVEHIV Cohort Plus
The role of fatty liver in the epidemic of advanced chronic liver disease among people living with HIV
Learn MoreStart-up
CTN 330: Predicting and evaluating anal cancer in HIV with novel biomarkers (The PEACH Study)
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men
Learn MoreOngoing
CTN 328: COVID-19 Vaccine in HIV
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.